Medical oncology: Zoledronic acid prevents bone loss in early-stage breast cancer

Nature Reviews Clinical Oncology

Volumn 6, Issue 4, 2009, Pages 191-192

  Bertoldo, Francesco ^a   Tonini, Giuseppe ^b   Vincenzi, Bruno ^b   Santini, Daniele ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; GOSERELIN; TAMOXIFEN; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE;

ARTICLE; BONE DENSITY; BONE DISEASE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG INTERMITTENT THERAPY; EARLY CANCER; FRAGILITY FRACTURE; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OSTEOLYSIS; OSTEOPOROSIS; OVARY FUNCTION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; SIDE EFFECT; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FEMALE; PHASE 3 CLINICAL TRIAL; REVIEW; SURVIVAL; TREATMENT OUTCOME; WOMEN'S HEALTH;

ANTINEOPLASTIC AGENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; OSTEOPOROSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 67649572936     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.24     Document Type: Article

References (6)

1. Gnant, M. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCsG-12 bone-mineral density substudy. Lancet Oncol. 9 840-849 (2008).
2. Saad, F. et al. Cancer treatment-induced bone loss in breast and prostate cancer. J. Clin. Oncol. 26, 5465-5476 (2008).
3. Ding, H. & Field, T. S. Bone health in postmenopausal women with early breast cancer: How protective is tamoxifen? Cancer Treat. Rev. 33, 506-513 (2007).
4. Greenspan, S. L. et al. significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 137, 875-883 (2002).
5. Seeman, E. Bone quality: The material and structural basis of bone strength. J. Bone Miner. Metab. 26, 1-8 (2008).
6. Brufsky, A. et al. integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13, 503-514 (2008).